CYP (ASX) U.K. approval received for CLI trial

Originally posted by Sector: ↑

Cynata Therapeutics (CYP)Rating: Buy | Risk: High | Price Target: $3.00

UK Regulatory Authority Approves Cynata's Phase 2 Clinical Trial in Critical Limb Ischaemia

EVENT: Further positive developments for CYP and its Cymerus MSC platform continue to support the outlook for both iPSC derived cells and our CYP investment thesis. Shaw and Partners forecasts and recommendation remain unchanged as does our 12 month TP.

HIGHLIGHTS: CYP has announced that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with its Phase 2 clinical trial of the Cymerus™ mesenchymal stem cell (MSC) product CYP-002 in patients with critical limb ischaemia (CLI).

CYP anticipates conducting the clinical trial at multiple centres in the UK and Australia. The trial is expected to start this quarter and involve the recruitment of ~90 patients with advanced CLI, cost are yet to be finalised. The UK is a reputable regulator recognised for good quality trials data outcomes, but it is also a relatively quick path to conducting clinical trials. Ultimately though CYP recognises it will have to go down the regulatory path in other major jurisdictions (e.g. U.S. FDA) if it is to fully access and monetise the CLI treatment opportunity which is forecast to reach a global value of US$5.4 billion by 2025.· The approval also confirms the successful implementation of the Company's strategy to use the positive Phase 1 trial of Cymerus MSCs in graft versus host disease to support direct progression from preclinical to Phase 2 clinical studies for CLI and multiple other indications. We expect this to include the indications CYP has recently generated successful pre-clinical data for.

Essentially the acceptance based on CYP's graft versus host disease phase 1 data fast tracks CYP's other programs which adds further appeal to potential licensing.· CLI is an advanced stage of peripheral artery disease (PAD), which is a narrowing of arteries in the limbs, particularly the legs. The risk of PAD is increased in patients with diabetes, obesity or high blood pressure and also in people who smoke. CLI often results in amputation of the affected limb and is a major risk factor for cardiovascular events such as heart attack.

There are 230,000 addressable events per year.· As previously announced, in a preclinical study in a mouse model of CLI, treatment with Cymerus MSCs led to significantly higher blood flow in the ischaemic limb and protection against muscle damage, fibrosis, and limb loss.

RECOMMENDATION: Since Shaw and Partners initiated coverage on CYP in May 2017 it has licensed its CYP-001 to Fujifilm and appreciated 190%. We expect further out performance as CYP i) moves CYP-001 into GvHD phase 2 trials in 2020, ii) partners a number of other undisclosed indications which it has disclosed it is currently negotiating, and iii) begins the NHMRC funded phase 2 Osteoarthritis clinical trial expected 2019-20. This trial in 448 patients will not only be one of the largest MSC trials ever undertaken, but targets a market opportunity estimated at USD 11.6b by 2025. Our BUY rating is reaffirmed.

Expand

seriously, all it takes to get 2x GA's these days is to cut and paste an analyst report?

yes i'm jealous.. never mind, carry on.

No.	Vol.	Price($)
3	5279	24.5¢

No.

Vol.

Price($)

5279

24.5¢

Price($)	Vol.	No.
25.5¢	187726	1

Price($)

Vol.

No.

25.5¢

187726

No.	Vol.	Price($)
3	5279	0.245
1	2000	0.240
1	4255	0.235
2	15173	0.230
3	102102	0.200

No.

Vol.

Price($)

5279

0.245

2000

0.240

4255

0.235

15173

0.230

102102

0.200

Price($)	Vol.	No.
0.255	187726	1
0.265	73392	3
0.270	30000	1
0.280	3334	1
0.290	4125	2

Price($)

Vol.

No.

0.255

187726

0.265

73392

0.270

30000

0.280

3334

0.290

4125

(20min delay)
Last 24.5¢		Change 0.000(0.00%)		Mkt cap ! $44.23M

Open	High	Low	Value	Volume
24.5¢	24.5¢	24.5¢	$1.583K	6.461K

seriously, all it takes to get 2x GA's these days is to cut and...

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GreenX picks up prospective copper project in Germany

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Is oil undervalued?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

seriously, all it takes to get 2x GA's these days is to cut and...

Top Stories

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GreenX picks up prospective copper project in Germany

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Is oil undervalued?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News